Long before the Falk Foundation e.V. existed, it was clear to Dr. Herbert Falk that he could not continue to visit doctors all over Germany by himself. In the company’s early years there was not sufficient money to provide field staff, and so in the mid-1960s the young entrepreneur decided to raise awareness for his small company by organizing and supporting postgraduate courses for doctors. This form of support was accompanied by a growing selection of literature. Since then many helpful brochures on symptoms, diagnosis and therapies have been made available for interested doctors and later for patients too. The many wall charts providing overviews in poster form, of, for example, metabolism of the liver, became well-known.
New ground was broken as regards size of the congresses and international participation in October 1967 with the organization of the “Ikterus” symposium in Freiburg. 800 doctors and scientists from 18 countries attended this congress which marked the birth of the international Falk Symposia. Since then there have been over 200 international Falk Symposia and Workshops, and more than 120,000 scientists from over 100 nations have taken part. Of the many Falk Symposia, the Falk Liver Weeks, which have taken place every three years since 1976 in Basel, and which returned to Freiburg from 2003 onwards, have been the most important with regard to the number of participants and international recognition along with the new Falk Gastro Congresses.
As the work involved in the various congress and literature service activities was continually increasing, and in order to demonstrate scientific independence and its importance to the outside world, the Falk Foundation e.V. was founded in 1978. Since then, as well as the international symposia in Germany, a number of seminars and Gastro Fora and around 600 postgraduate courses and doctor-patient seminars have taken place every year under the autonomous organization of the Falk Foundation e.V. Following the wife of the founder, who died in 2008, today are the two children, Dr. Martin Falk and Carola Falk, chairman of the Falk Foundation e.V.
Klinische Studie zur Beurteilung eines neuen, sich in der Erprobung befindlichen biologischen Medikaments. Der Name der Studie ist TRUST-2, was für „TRichUris Suis ova Trial“ steht.
Mehr als 200 Patienten mit MORBUS CROHN haben das sich in der Erprobung befindende Studienmedikament bisher in klinischen Studien eingenommen.
Die Studien zeigen eine Abnahme der Krankheitsaktivität und in der Mehrzahl der Fälle wurde Remission (beschwerdefreie Phase) erzielt. Die bisher beobachteten Nebenwirkungen betrafen zumeist den Verdauungstrakt.